StockWatch
·

AMRUTANJAN HEALTH CARE LTD.-$ Q1 FY27 Results

AMRUTANJANQ1 FY27 Results
Filing
Result:Weak· Market: CrashedMargin squeeze
MetricValueQ4 FY26Q1 FY26
Revenue102.97 Cr31.3%9.5%
Total Income106.78 Cr30.9%8.4%
Expenditure98.69 Cr21.6%13.2%
PBT6.07 Cr71.1%46.3%
Net Profit4.37 Cr73.0%47.5%
OPM4.09%7.89pp4.89pp
NPM4.09%6.39pp4.35pp
EPS1.5173.0%47.4%
View full financials

Revenue grew 9.5% YoY but adjusted PAT fell 47.5% on sharp margin compression (OPM 8.98%→4.09%), a clear below-par quarter for the consumer/pharma segment.

Q1 FY-2027 RESULTS · AMRUTANJAN

Amrutanjan Q1 FY27: PAT falls 47% YoY to ₹4.37 Cr as lease-rent hit, hygiene losses widen

PAT -47.47% YoY · revenue +9.49% · margins compressing

11 Aug 2026 · 3 min read
Revenue

₹102.97 Cr

+9.49% YoY

PAT (standalone)

₹4.37 Cr

-47.47% YoY

Net margin

4.09%

-4.3pp YoY

EPS

₹1.51

Amrutanjan's standalone (its only reported basis — the company has no subsidiaries) PAT for Q1 FY27 came in at ₹4.37 Cr, down 47.5% year-on-year from ₹8.31 Cr and down 73.0% sequentially from ₹16.19 Cr in the seasonally strong Q4 FY26. Revenue rose 9.5% YoY to ₹102.97 Cr from ₹94.05 Cr but fell 31.3% QoQ from ₹149.77 Cr — the March quarter is the balm season peak, so the sequential drop is largely seasonal and not itself a red flag. Net margin compressed sharply to ~4.1% of total income, versus 8.44% a year ago and 10.48% last quarter.

The scoreboard

Q1 FY-2027 vs prior quarters

Standalone P&L, ₹ Crore
Q1 FY-2027QoQYoY
Revenue₹102.97 Cr-31.2%+9.5%
Expenses₹98.69 Cr-21.6%+13.2%
PAT₹4.37 Cr-73.04%-47.47%
Net margin4.09%-6.4pp-4.3pp
EPS₹1.51-73%-47.4%

The headline decline is inflated by a one-off: a ₹2.03 Cr exceptional charge tied to settling a long-running Tamil Nadu HR&CE lease-rent dispute, under which the company paid ₹9.74 Cr in total arrears on August 1, 2026. Excluding this, pre-exceptional PBT was ₹8.10 Cr and adjusted PAT works out to roughly ₹5.82 Cr — still down about 29.9% YoY, so the underlying business, not just the one-off, is weaker. Segment data point to the source: the Women's Hygiene & Personal Care segment's loss widened to ₹2.88 Cr from a marginal ₹0.15 Cr profit a year ago, consistent with ramp-up costs from the newly commissioned ₹150 Cr sanitary napkin plant (announced August 5, 2026). Core OTC Products segment profit also slipped 8.5% YoY to ₹9.87 Cr from ₹10.79 Cr, while the Beverages segment's loss narrowed to ₹1.26 Cr from ₹3.00 Cr.

499.87523.45547.03570.6594.18533.7505-0806-0106-2307-1608-0708-11Q1 FY-2027 results
The tape into the print — daily closes, last 3 months

The stock went into the print at ₹533.75, down 1.2% over the past month of trading.

₹ Cr
07.2614.5221.7915.18Q4 FY25rev ₹135 Cr8.31Q1 FY26rev ₹94 Cr13.96Q2 FY26rev ₹118 Cr19.45Q3 FY26rev ₹141 Cr16.19Q4 FY26rev ₹150 Cr4.37Q1 FY27rev ₹103 Cr
Quarterly standalone PAT, ₹ Crore
Beyond the headline

What the summary numbers don't show

EPS ₹1.51 (not annualised) vs ₹2.87 YoY and ₹5.60 QoQ

No analyst consensus estimates for this quarter were found in a web search, and the company has no formal quarterly guidance on record in our data or online, so the print cannot be graded against a specific external bar; management's press release commentary was not available for this filing either. The lease-rent settlement and the plant commissioning both fell inside this quarter and, taken together, explain most of the swing in reported profitability. Separately, the board fixed September 11, 2026 as the record date for the final dividend and set the 89th AGM for September 23, 2026 — both administrative and unrelated to the operating numbers.

  • W1

    Whether the Women's Hygiene segment's loss narrows in coming quarters as the ₹150 Cr sanitary napkin plant ramps past its ₹2.88 Cr Q1 FY27 loss

  • W2

    Whether the lease-rent matter is now fully closed after the ₹9.74 Cr arrears settlement, with no further exceptional provisioning ahead

  • W3

    Whether core OTC pre-exceptional margin recovers from 7.9% of revenue back toward the ~12.0% seen in Q1 FY26

No consolidated statement (company has no subsidiary/associate/JV, note 3). PBT includes a ₹2.0275 Cr exceptional item (lease-rent arrears settlement, note 6); pre-exceptional PBEIT was ₹8.0969 Cr. Figures converted from INR Lakhs.

Informational and educational content only. Not investment advice.

AMRUTANJAN HEALTH CARE LTD.-$ (AMRUTANJAN) Q1 FY27 Results — StockWatch